Fludrocortisone Acetate Tablets (Aspen) (50455)
Fludrocortisone Acetate Tablets (Aspen) (50455)

The following Competition guidance note provides comprehensive and up to date legal information covering:

  • Fludrocortisone Acetate Tablets (Aspen) (50455)
  • Case facts
  • Timeline
  • Commentary
  • Related cases

CASE HUB

See further, timeline, commentary andrelated cases

Case facts

Outline CMA Article 101 TFEU/Chapter I and Article 102 TFEU/Chapter II investigation into Aspen’s alleged breach of competition law in relation to the supply of Fludrocortisone Acetate Tablets in the UK.

Latest developments On 3 October 2019, the CMA issued a statement of objections to Aspen, Amilco and Tiofarma. In addition, the CMA formally accepted Aspen’s offer of commitments, including paying the NHS £8m and ensuring, in the future, that there will be at least two suppliers of fludrocortisone in the UK.

Parties • Aspen Pharmacare Holdings Ltd, Aspen Global Inc., Apsen Pharma Ireland Ltd, and Aspen Pharma Trading Ltd (together, Aspen). Aspen is a multinational pharmaceutical group with its headquarters in South Africa. It owns a broad portfolio of branded and generic prescription products that are sold to wholesalers, hospitals and pharmacies in over 100 countries.

• Amilco is a UK based company that specialise in the sale of medical stock.

• Tiofarma is a Dutch based pharmaceutical company. It develops and produces a wide variety of medicines throughout Europe.